[{"address1": "28 Wells Avenue", "address2": "3rd Floor", "city": "Yonkers", "state": "NY", "zip": "10701", "country": "United States", "phone": "914 207 2300", "website": "https://www.contrafect.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Messinger CPA", "age": 47, "title": "CEO, President, CFO & Principal Accounting Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 543138, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Natalie  Bogdanos J.D.", "age": 53, "title": "General Counsel, Corporate Secretary & Data Protection Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 531204, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Salamone P.H.R., SPHR", "title": "Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Woodnutt", "age": 65, "title": "Senior Vice President of Translational Sciences & Preclinical Development", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William Garrett Nichols M.D., M.S.", "age": 53, "title": "Interim Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.03, "open": 0.03, "dayLow": 0.0252, "dayHigh": 0.0379, "regularMarketPreviousClose": 0.03, "regularMarketOpen": 0.03, "regularMarketDayLow": 0.0252, "regularMarketDayHigh": 0.0379, "beta": 0.294, "forwardPE": -0.021033334, "volume": 109422, "regularMarketVolume": 109422, "averageVolume": 121820, "averageVolume10days": 68260, "averageDailyVolume10Day": 68260, "fiftyTwoWeekLow": 0.023, "fiftyTwoWeekHigh": 6.95, "fiftyDayAverage": 0.04296, "twoHundredDayAverage": 0.820735, "currency": "USD", "enterpriseValue": -2565618, "floatShares": 10693028, "sharesShort": 115971, "sharesShortPriorMonth": 14111, "sharesShortPreviousMonthDate": 1694736000, "dateShortInterest": 1697155200, "sharesPercentSharesOut": 0.0216, "heldPercentInsiders": 0.00014999999, "heldPercentInstitutions": 0.05546, "shortRatio": 1.18, "shortPercentOfFloat": 0.0275, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -24138000, "forwardEps": -1.5, "lastSplitFactor": "1:80", "lastSplitDate": 1676419200, "enterpriseToEbitda": 0.085, "52WeekChange": -0.99385244, "SandP52WeekChange": 0.21733451, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CFRXQ", "underlyingSymbol": "CFRXQ", "shortName": "ContraFect Corporation", "longName": "ContraFect Corporation", "firstTradeDateEpochUtc": 1410528600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1e656d0d-0429-34ba-94fa-ec3f5e2821ff", "messageBoardId": "finmb_112206719", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.03155, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 5413000, "totalCashPerShare": 0.506, "ebitda": -30055000, "totalDebt": 2553000, "quickRatio": 0.439, "currentRatio": 0.529, "returnOnAssets": -1.1744, "freeCashflow": -24600750, "operatingCashflow": -35586000, "financialCurrency": "USD", "trailingPegRatio": null}]